Healthcare Industry News: La Jolla Pharmaceutical Company
News Release - September 12, 2007
Nventa Strengthens Management Team With Vice President Of FinanceDavid Duncan, Jr. Has Significant Financial Experience in Biotechnology
SAN DIEGO, CA, Sept. 12 (HSMN NewsFeed) - Nventa Biopharmaceuticals Corporation (TSX:NVN ) announced today that David Duncan, Jr., has joined the Company as its Vice President of Finance.
"With his successful track record serving biotechnology companies, we are very pleased to welcome David to Nventa," said Gregory M. McKee, President and Chief Executive Officer of Nventa. "His extensive experience in financial and operations management, including public stock offerings, financial reporting, investor relations, treasury and cash management, should prove invaluable as we advance our lead therapeutic vaccine candidate, HspE7, and other future CoVal(TM) fusion products."
Mr. Duncan has extensive experience in financial and operations management, and has been involved with several successful biotechnology companies including La Jolla Pharmaceutical Company, Tanox, Inc. and Hybritech Incorporated. Mr. Duncan received his bachelor's degree in Finance and his MBA at Indiana University in Bloomington, Indiana.
About Nventa Biopharmaceuticals Corporation:
Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The Company is publicly traded on the Toronto Stock Exchange under the symbol NVN. For more information about Nventa Biopharmaceuticals Corporation, please visit the Company's website located at www.nventacorp.com.
Source: Nventa Biopharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.